TABLE 1.
CLINICAL FEATURES OF SUBJECTS
| Control | COPD | P Value | |
|---|---|---|---|
| n of subjects | 16 | 14 | |
| Age (yr) | 63.8 ± 2.2 | 60.2 ± 2.3 | 0.27 |
| Gender (M/F) | 13/3 | 8/6 | 0.27 |
| Histology of lung tumor | |||
| Adenocarcinoma | 7 | 7 | |
| Squamous cell carcinoma | 6 | 4 | |
| Large cell carcinoma | 2 | 1 | |
| Carcinoid | 1 | 0 | |
| No tumor* | 0 | 2 | |
| Height, cm | 169.6 ± 2.0 | 173.3 ± 2.5 | 0.29 |
| Weight, kg | 71.1 ± 3.3 | 71.6 ± 4.1 | 0.57 |
| Smoking (pack-years) | 43.2 ± 7.6 | 43.7 ± 4.3 | 0.63 |
| Current smoker† | 6 | 6 | 0.82 |
| GOLD stage (I/ II/ III/ IV) | 0/ 0/ 0/ 0 | 1/ 6/ 5/ 2 | |
| Pre-medications | |||
| LAMA | 0 | 7 | |
| LABA | 0 | 7 | |
| ICS | 0 | 8 | |
| Oral steroids | 0 | 5 | |
| Theophylline | 0 | 2 | |
| Statins | 4 | 3 | |
| VC (% of predicted value) | 103.9 ± 2.6 | 90.1 ± 4.8 | 0.02 |
| FEV1 (% of predicted value) | 93.5 ± 2.6 | 49.2 ± 4.6 | <0.0001 |
| DlCO (% of predicted value)‡ | 86.6 ± 3.4 | 63.1 ± 5.2 | 0.003 |
Definition of Abbreviations: COPD = chronic obstructive pulmonary disease; DlCO = diffusion capacity for carbon monoxide; GOLD = Global Initiative for Chronic Obstructive Lung Disease; ICS = inhaled corticosteroids; LABA = long acting β-agonist; LAMA = long-acting muscarinic antagonist.
Values are mean ± SEM, except for sex, histology of lung tumor, current smoker, GOLD stage, and premedications (number).
*
These subjects were undergoing volume reduction surgery.
†
Current smoker defined as someone who has smoked 100 cigarettes in his or her lifetime and who currently smokes cigarettes.
‡
DlCO values are from 13 subjects of each group.